Skip to main content
OpenTrials
Completed

NCT Number: NCT05305456

Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Novel Coronavirus Pneumonia Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China

Loading trial locations.

About this study

The purpose of this study was to evaluate the efficacy and safety of Tanreqing capsule in the treatment of mild and common COVID-19. The trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial design. A total of 480 patients were divided into 2 groups: experimental group and control group 3:1. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • According to the Diagnosis and Treatment Plan for Pneumonia Infected by novel coronavirus (Trial Version 9), those who are in line with the diagnosis of novel coronavirus pneumonia and whose clinical classification is light and ordinary；
  • Aged greater than 18, with no gender limitation;
  • Symptom score greater than or equal 3 points;
  • Voluntarily accept the drug treatment and sign the informed consent.

Exclusion criteria

  • Patients with severe primary respiratory diseases or other pathogenic microbial pneumonia that needs to be differentiated from COVID-19;
  • immune deficiency disease, or use of immunosuppressants or glucocorticoids in the last 3 months;
  • pregnant and lactating women;
  • People with allergic constitution (allergic to more than two drugs or food or known allergic to the drug used in this study);
  • mentally ill persons or persons without self-awareness;
  • Patients whose expected survival time from screening is not more than 48 hours; (7) those who have been intubated or mechanically ventilated at the time of screening;

(8) In patients with serious primary diseases of heart, brain, liver and kidney, ALT and AST were 1.5 times higher than the upper limit of normal value; (9) Other conditions that the investigator considers inappropriate for clinical trial participation.

Treatment and study plan

Tanreqing capsule

Drug

3 capsules per time, 3 times a day

Other names: Basic treatment: Vitamin C effervescent tablet, 1g, once a day, warm boiled water after brewing, continuous administration for 7 days.

Tanreqing capsule simulator

Drug

3 capsules per time, 3 times a day

Other names: Basic treatment: Vitamin C effervescent tablet, 1g, once a day, warm boiled water after brewing, continuous administration for 7 days.

Primary outcomes

  1. The time from the first dose to sustained clinical recovery

    Time frame: 8 days

    Symptom domains and minors disappear completely within 7 days treatment period after randomization, and maintain it for 2 days without recurrence and the disease don't aggravate

Secondary outcomes

  1. Novel coronavirus N and ORF gene changes

    Time frame: 8 days

    Nucleic acid detection was performed on the 0, 1, 2, 3, 4, 5, 6 and 7 days respectively.

    The fluorescent quantitative PCR method was used to determine the Ct value of N gene and ORF gene in novel coronavirus nucleic acid detection. Negative: no Ct value or Ct value>40. Positive: Ct value<35. Ct value (cycle threshold) refers to the Ct value of nucleic acid detection, that is, the number of cycles required when the pcr fluorescence signal reaches the threshold.

  2. The time from the first dose/first testing positive of virus to testing sustained negative of virus within 7 days treatment period after randomization

    Time frame: 8 days

    Testing sustained negative of virus was defined two consecutive (at least 24 hours apart) nasal swabs with new coronavirus nucleic acid detection CT values 35 ,and the negative event date was defined by first negative occurrence.

  3. Effective rate of wind heat attacking lung syndrome

    Time frame: 8 days

    The time from the first dose to sustained clinical improvement defined total scores for symptom domains and minors was <3 within 7 days treatment period after randomization.

  4. Duration of disappearance of main symptoms of wind heat attacking lung syndrome

    Time frame: 8 days

    The time from the first dose to sustained complete disappearance within 7 days treatment period after randomization for every symptom domain, and these two outcomes definition were similar to the primary outcome.

  5. Weight conversion rate (ratio of light type to ordinary type and ordinary type to heavy type)

    Time frame: 90 days

    Proportion of patient experiencing progression to severe illness diagnosed by Trial draft version 9 of Diagnosis and Treatment Protocol for novel Coronavirus pneumonia within 7 days treatment period after randomization, during period from the end of 7 days treatment period to discharged from hospital and 3-month follow-up period after discharge.

Sponsors and collaborators

Lead sponsor

Jiangsu Famous Medical Technology Co., Ltd.

Industry

Collaborators

  • Ruijin Hospital

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Tanreqing Capsule Efficacy and Safety in the Treatment of COVID-19 (Mild and Common Type)

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 31, 2022
Registry last updated
Dec 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.